Martens T, Beck RW, Bailey R, et al. - In this randomized clinical trial, researchers sought to determine the efficacy of continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin without prandial insulin in primary care practices. This trial was performed at 15 centers in the US (registration from July 30, 2018, to October 30, 2019; follow-up completed July 7, 2020) and involved adults with type 2 diabetes receiving their diabetes care from a primary care clinician and treated with 1 or 2 daily injections of long- or intermediate-acting basal insulin without prandial insulin, with or without noninsulin glucose-lowering medications. Among 175 randomized candidates (mean [SD] age, 57 [9] years; 88 women [50%]; 92 racial/ethnic minority individuals [53%]; mean [SD] baseline HbA _1c level, 9.1% [0.9%]), 165 (94%) ended the trial. Continuous glucose monitoring, as opposed to blood glucose meter monitoring, resulted in significantly lower HbA _1c levels at 8 months in adults with poorly controlled type 2 diabetes treated with basal insulin without prandial insulin.